Enjoy complimentary customisation on priority with our Enterprise License!
The Gastroparesis Drugs Market size is estimated to grow by USD 1.42 billion at a CAGR of 3.69% between 2023 and 2028.
Gastroparesis drugs market Share
For More Highlights About this Report, Download Free Sample in a Minute
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
One of the key factors driving the gastroparesis drugs market growth is the rising global burden of diabetes. The global; burden of diabetes is increasing at a rapid pace. For instance, in 2021, approximately 537 million adults aged 20-79 years had diabetes. In addition, the growing prevalence of Type 1 and Type 2 diabetes increases the chances of gastroparesis significantly.
Moreover, diabetes can harm neurons, including the vagus nerve, as well as unique cells in the stomach wall known as pacemaker cells. In addition, some of the main factors that are causing diabetes include obesity, smoking, a sedentary lifestyle, and growing urbanization. Furthermore, there is an increasing prevalence of diabetes in the older population. Hence, such factors are driving the market growth during the forecast period.
A key factor shaping the gastroparesis drugs market growth is the increasing number of clinical research. There has been a rapid expansion in the globalization of clinical research over the last two decades. Some of the main factors include organized trials, volunteers, accessibility of qualified local investigators, improved infrastructure facilities, and the low cost of conducting clinical trials in developing nations.
Moreover, the clinical advantages for disease-specific therapeutic incorporate faster and more accurate disease analysis and potential diminishing in sample size and time of clinical trials, which will accelerate drug development. In addition, the NIH-funded GpCRC was initiated to improve the understanding of the pathogenesis and history of gastroparesis and to advance the diagnosis and therapy of patients affected with this condition. Hence, such factors are driving the market growth during the forecast period.
Serious side effects of gastroparesis drugs are one of the key challenges hindering the gastroparesis drugs market growth. Prokinetics is the first line of treatment for gastroparesis, which are drugs that increase gastrointestinal motility. In addition, Metoclopramide is one such prokinetic drug and is the only drug approved by the US FDA to treat gastroparesis.
Moreover, it can also aid in relieving nausea by stimulating the contractions of the stomach muscles. In addition, a newer medication, domperidone, with fewer side effects, is also available but with restricted access. Therefore, the serious side effects associated with gastroparesis drugs can negatively impact the market. Hence, it will hinder the market growth during the forecast period.
The prokinetic agents segment is estimated to witness significant growth during the forecast period. This segment is often employed to aid in addressing the underlying problem of delayed stomach emptying in patients with gastroparesis. One of the main reasons is that these drugs address the fundamental pathophysiology that characterizes gastroparesis, these medications are popularly used in their treatment. In addition, prokinetic medications may not always cause a corresponding change in stomach emptying to match the symptomatic response.
Get a glance at the market contribution of various segments Download the PDF Sample
The prokinetic agents segment was the largest segment and was valued at USD 3.52 billion in 2018. Moreover, several prokinetic medications, such as domperidone and metoclopramide, also have antiemetic qualities. In addition, more recent drugs with limited adverse effects and proven efficacy, such as ghrelin, motilin, 5-HT4 receptor agonists, and dopamine receptors such as metoclopramide, are also being studied in treating gastroparesis. Furthermore, it also comprises agents such as domperidone, erythromycin, and cisapride. Reglan which is a metoclopramide is used for gastroparesis indication in the US and is offered by Ani Pharmaceuticals.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
One of the main factors that significantly contributes to the market growth in North America is the increasing prevalence of diabetes in the region. For example, as per the Centers for Disease Control and Prevention (CDC), in 2022, more than 130 million adults had diabetes in the US. In addition, some of the key regions in North America with the highest proportion of people with diabetes include the US, Canada, and Mexico. Some of the main reasons include unhealthy eating habits and the physically inactive or sedentary lifestyles of people, which leads to obesity. Hence, such factors are driving the market growth in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories: The company offers gastroparesis drug such as Ganaton OD and Ganaton.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
|
Gastroparesis Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
166 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 3.69% |
|
Market growth 2024-2028 |
USD 1.42 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
3.53 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 37% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Disease Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
